Jeremy G. Stone, MD, is a board eligible neurosurgeon with CAST-accredited subspecialty fellowship training in neuroendovascular surgery, completing both residency and fellowship at the University of Pittsburgh. He currently practices with Great Lakes Neurosurgery and Neurointervention at UPMC Hamot in Erie, Pennsylvania serving as clinical assistant professor and director of cerebrovascular surgery.
Dr. Stone enjoys general neurosurgery with clinical focus on open cerebrovascular, neuroendovascular, minimally invasive techniques, and spine deformity. He also leads scientific discovery with participation as site principal investigator in several clinical trials.
Specialized Areas of Interest
Board Certifications
American Board of Neurological Surgery (board eligible)
Hospital Privileges
Professional Organization Membership
Professional Activities
Education & Training
- BS, Biology/Psychology, Case Western Reserve University, 2009
- MD, University of Hawaii, 2014
- CAST-Accredited Fellowship, Neuroendovascular Surgery, University of Pittsburgh, 2020
- Residency, Neurological Surgery, University of Pittsburgh, 2021
Honors & Awards
- Best Off-Service Teacher Award, Orthopedic Surgery Residency, UPMC Hamot, 2021
- UPMC Medical Education LEAP Award for Patient Safety and Quality Improvement, 2017, 2020
- Oral Presentation Award, Second Annual Graduate Medical Education Quality and Safety Symposium, University of Pittsburgh, 2019
- Best Resident Research Presentation Runner Up, Stuart Rowe Society Lectureship, University of Pittsburgh, 2019
- Top Score, American Board of Neurological Surgery Written Board Exam, 2018
- Frank and Mary McDowell Award for Excellence in Surgery, 2014
- Windsor and Mary Cutting Excellence in the Basic Sciences Award, 2014
- Bernard Yim Award for Top Performance in Internal Medicine Clerkship, American College of Physicians, University of Hawaii John A. Burns School of Medicine, 2013
- Po'okela and Noi'i Award for Outstanding Research, 2014
- American College of Physicians Bernard Him Award for Top Performance in Internal Medicine, 2013
Research Activities
• Multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA (OCEANIC-STROKE).
Phase 3 program of the Oral faCtor Eleven A iNhibitor asundexLan as novel anti-thrombotiC STROKE study.
• Comparison of Anti-coagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA).
Two-stage Phase III trial randomizing subjects with stroke attributed to 70-99% intracranial atherosclerotic stenosis to 1. ticagrelor + aspirin, 2. low dose rivaroxaban + aspirin, 3. clopidogrel + aspirin.
• Protection against Emboli during caRotid artery stenting using a 3-in-1 delivery system comprised oF a pOst-dilation balloon, integRated eMbolic filter, and A Novel Carotid stEnt II (PERFORMANCE II).
Prospective, single-arm, multicenter clinical trial to evaluate the safety and effectiveness of the Neuroguard IEP System for the treatment of carotid artery stenosis.